Visiongain Publishes Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-2031

16 February 2021
Pharma

Visiongain has published a new report on Artificial Intelligence (AI) in Pharmaceutical Market Report 2021-2031: Forecasts by Application (Drug Discovery, Precision Medicine, Medical Imaging & Diagnostics, Research), by Technology (Machine Learning, Other Technologies), by Offering (Hardware, Software, Services), by Deployment (Cloud, On-Premises) AND Regional and Leading National Market Analysis PLUS Analysis of Leading AI Companies AND COVID-19 Recovery Scenarios.

The global AI in pharmaceuticals market size was valued at US$ xx million in 2020 and is anticipated to reach US$ xx million in 2026 while growing at a CAGR of xx% during the first half of the forecast period i.e., 2021 to 2026. The global market size is further projected to reach US$ xx million by 2031 at a CAGR of xx% from 2026 to 2031. The overall CAGR for the global virus diagnostic kits market is expected to be xx% from 2021 to 2031.

Embracing Technology to Revolutionize Pharmaceutical Industry
There are other fields where the R&D process can be influenced by AI and machine learning. Better approaches to predict chemicals' properties in order to reduce the amount of substances that need to be synthesized is obviously an opportunity. This would allow for the consideration of a larger chemical universe and enrich the 'chemical palette' open to medicinal chemists. Another field where researchers are starting to use AI and machine learning is mining genomic, proteomic and metabolic data for improved disease biomarkers and medication efficacy surrogate markers. For example, the time taken to examine cancer tumor scans or neurological condition brain scans may be drastically reduced. Further downstream, AI and deep learning are also used to evaluate real-world result data, wearable device data and other sensors. Predictive toxicology is already in its infancy and, potentially, businesses will still be able to detect any possible safety hazards with compounds even sooner by harnessing the true potential of AI. This advanced technology will also promote predictive medicine and better stratification of patients for clinical trials and this can lead to an improvement in performance based on greater effectiveness in clinical trials since it is possible to better choose the most desirable patient pool.

What are the Opportunities for AI in Drug Discovery?
AI is seen to give drug development a strategic edge, so it is expected to be introduced easily and generally. The implications of the market adjusting to accept the modern reality will eventually take place, and the strain to embrace the new ways of working will be felt by late adopters for fear of dropping out of the race. They would need to adapt or perish if any larger and more developed players are already lagging behind.

Competitive Landscape
• Microsoft Corporation
• NVIDIA Corporation
• IBM Corporation
• Alphabet Inc.
• Atomwise, Inc.
• Deep Genomics
• Cloud Pharmaceuticals, Inc.
• Insilico Medicine
• BenevolentAI
• Exscientia
• Biosymetrics
• Euretos
• Insitro
• Cyclica
• Biovista
• OWKIN, INC.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever